Table 1.
Peptide-based drug/diagnostic approved by the FDA between 1 January 2016 and 30 September 2022 [13,14,15,16,17,18,19].
| Active Ingredient a | Trade Name a | Indication | Year of Approval |
|---|---|---|---|
| Lixisenatide | AdlyxinTM | Type 2 diabetes | 2016 |
| Abaloparatide | TymlosTM | Osteoporosis | 2017 |
| Angiotensin II | GiaprezaTM | Control of blood pressure | 2017 |
| Etelcalcetide | ParsabivTM | Hyperparathyroidism | 2017 |
| Macimorelin | MacrilenTM | Adult growth hormone deficiency | 2017 |
| Plecanatide | TrulanceTM | Chronic idiopathic constipation | 2017 |
| Semaglutide | OzempicTM | Type 2 diabetes | 2017 |
| Afamelanotide | ScenesseTM | To prevent skin damage and pain after exposure to the sun. | 2019 |
| Bremelanotide | VyleesiTM | Hypoactive sexual desire in premenopausal women | 2019 |
| Setmelanotide | ImcivreeTM | Obesity and hunger | 2020 |
| Dasiglucagon | ZegalogueTM | Hypoglycemia in diabetes | 2021 |
| Difelikefalin | KorsuvaTM | Pruritus | 2021 |
| Melphalan flufenamide | PepaxtoTM | Multiple myeloma | 2021 |
| Odevixibat | BylvayTM | Pruritus | 2021 |
| Pegcetacoplan | EmpaveliTM | Paroxysmal nocturnal hemoglobinuria | 2021 |
| Voclosporin | LupkynisTM | Lupus nephritis | 2021 |
| Vosoritide | VoxzogoTM | Achondroplasia (Dwarfism) | 2021 |
| Gadopiclenol | Elucirem™ | Diagnostic of lesions in the central nervous system | 2022 |
| Terlipressin | TerlivazTM | Low blood pressure | 2022 |
| Tirzepatide | MounjaroTM | Type 2 diabetes and obesity | 2022 |
a Trade name used in the USA.